ONCT - Oncternal Therapeutics

-

$undefined

N/A

(N/A)

Oncternal Therapeutics NASDAQ:ONCT Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.

Location: 12230 El Camino Real Ste 300, California, 92130-2090, US | Website: www.oncternal.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-12.83M

Cash

14.58M

Avg Qtr Burn

-6.658M

Short % of Float

0.53%

Insider Ownership

9.23%

Institutional Own.

12.07%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ONCT-808 (CAR-T) Details
Hematologic malignancies, Cancer, B-cell lymphoma

Phase 1/2

Data readout

ONCT-534 Details
Cancer, Castration-resistant prostate cancer

Failed

Discontinued

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma

Failed

Discontinued

Failed

Discontinued

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Cancer, Mantle cell lymphoma

Failed

Discontinued

ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details
Relapsed/refractory Ewing sarcoma, Cancer

Failed

Discontinued